Results 241 to 250 of about 1,877,858 (304)

A Geographically Sensitive Neighborhood Exposome-Wide Association Study for Breast Cancer Survival.

JAMA Netw Open
Boyle J, Zhao H, Barry KH, Shen J, Miller CA, Knott CL, Fuemmeler BF.   +6 more
europepmc   +1 more source

Left bundle branch area pacing vs right ventricular pacing for atrioventricular block: the MELOS RELOADED study. [PDF]

Eur Heart J
Jastrzębski M, Kiełbasa G, Cano O, Curila K, Zanon F, Pestrea C, De Pooter J, Luermans J, Rademakers LM, Žižek D, Grieco D, Huybrechts W, Krisai P, Whinnett ZI, Moskal P, Valiton V, Navarrete-Navarro J, Stros P, Deluca F, Cicala E, Özpak E, Vernooy K, Burri H.   +22 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Prognostic impact of monocyte percentage and extranodal involvement in classical hodgkin lymphoma: A multicenter real-world study of 547 chinese patients. [PDF]

Ann Hematol
Wang L, Pi J, He X, Zhang W, Liu H, Bai J, Zhao Y, Zhong K, Bao L, Gao S, Li Z, Wu J, Zhou H, Chen Y, Liu S, Jing H.   +15 more
europepmc   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis. [PDF]

ESMO Gastrointest Oncol
Deac O, Redaniel MT, McDevitt J, Brennan A, Fitzpatrick D, Coleman HG, Turkington RC, Donohoe C, Narayanasamy R, Elliott JA, Reynolds J, O'Sullivan J, Lowery MA.   +12 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial). [PDF]

J Transl Med
Piedra A, Guinart-Cuadra A, Martínez-Recio S, Mulet M, Zamora C, Osuna-Gómez R, Cantó E, Ortiz MA, Alejandre J, Barba A, Sanz-Beltrán J, Serra-López J, Isla D, Arriola E, Paz-Ares L, Diz-Taín MP, Moreno AL, Callejo Á, Vidal S, Majem M.   +19 more
europepmc   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source